- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01909115
Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease
Randomized Trial of Two Maintenance Doses of Vitamin D and Trace Element Status in Children With Chronic Kidney Disease
Vitamin D deficiency is common in the general population and more common in children with chronic kidney disease. Vitamin D is very important for bone health, especially in children with chronic kidney disease. To date, several studies using different doses of vitamin D have been tried to correct vitamin D deficiency, but none has been completely successful. The investigators are comparing two different doses of vitamin D to determine which one is more effective at correcting and maintaining normal blood levels of vitamin D. The investigators hypothesize that a higher percentage of children receiving a higher dose of vitamin D will be vitamin D replete at the end of 6 months.
This study will enroll 80 children 9 to 18 years old who have chronic kidney disease (CKD) and can take pills. They will be enrolled from Chronic Renal Insufficiency Clinic, the Hemodialysis Unit, Peritoneal Dialysis Clinic and Transplant Clinic at Children's Healthcare of Atlanta.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Vitamin D has a critical role in bone metabolism. In addition, there is increasing evidence that vitamin D has an important role in many other areas, including cardiovascular health, immune function, and prevention of autoimmune diseases and certain malignancies. In patients with CKD, there are a variety of abnormalities in mineral metabolism that lead to bone disease.
After the investigators obtain informed consent and assent, children will be randomly assigned to either low dose (1000 units daily) or high dose (4000 units daily) vitamin D pills (50% in each group). Participants will take vitamin D capsules every day for for 6 months. Vitamin D levels will be obtained at baseline, 3 months and 6 months. The study visits will be at the same time as routine clinic visits when the children are having blood drawn for routine care. At the end of the study, the investigators will compare the percentage of patients who have normal vitamin D levels at 6 months in the two groups. The investigators will also describe the percentage of patients who have elevated or low levels of trace elements.
The two doses of vitamin D in this study are within the dosing range recommended by the Institute of Medicine, and thus the investigators do not anticipate any adverse effects. Vitamin D toxicity could theoretically occur, and an elevated vitamin D level at 3 months would be an indication to withdraw a patient from the study.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Childen's Healthcare of Atlanta
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patient's parent/legal guardian must be willing and able to give written informed consent and the patient must be willing to give written informed assent if applicable
- Estimated glomerular filtration rate < 60 mL/min/1.73 m2 body surface area or recipient of a kidney transplant
- 9-21 years old
- Able to swallow pills
Exclusion Criteria:
- Liver failure
- Malabsorption
- Current calcium level >10.5 mg/dL
- History of hypercalcemia (Ca >11 mg/dL) during the preceding 6 months
- Current treatment with an antiepileptic drug or other medications that may affect vitamin D metabolism (e.g., phenobarbital, phenytoin, rifampicin)
- History of hypervitaminosis D
- Completion of a course of high dose vitamin D within the preceding 2 months
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: 1000 IU of Vitamin D Daily
Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
|
1000 IU of Vitamin D will be administered in capsule form, once daily.
|
Expérimental: 4000 IU of Vitamin D Daily
Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
|
4000 IU of Vitamin D will be administered in capsule form, once daily.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Percentage of Participants with Adequate Vitamin D Level
Délai: Month 6
|
Vitamin D sufficiency will be assessed as the percentage of participants with a vitamin D level >30 ng/ml.
|
Month 6
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Larry Greenbaum, MD, PhD, Emory University
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB00067067
- EmoryPedNeph-001 (Autre identifiant: Other)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Maladie rénale chronique
-
PfizerComplétéLeucémie, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) PositifFrance, États-Unis, Canada, Espagne, Tchéquie, Singapour, Thaïlande, Danemark, Norvège, Corée, République de, Finlande, Hongrie, Suède, Pays-Bas, Italie, Allemagne, Ukraine, Afrique du Sud, Taïwan, Australie, Belgique, Israël, Mexique, Pologn... et plus
Essais cliniques sur 1000 IU of Vitamin D3
-
Cedars-Sinai Medical CenterRésiliéCarence en vitamine D | La maladie de CrohnÉtats-Unis
-
Bumi HermanComplétéCOVID-19 [feminine]Indonésie
-
Tirang R. Neyestani, Ph.D.National Nutrition and Food Technology InstituteComplétéStatut maternel en vitamine DIran (République islamique d
-
Medical University of WarsawComplété
-
King Faisal Specialist Hospital & Research CenterRetiréCarence en vitamine DArabie Saoudite
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RésiliéCarence en vitamine D | Des chutesÉtats-Unis
-
Hospital Clinic of BarcelonaInconnueObésité | Gastrectomie | Pontage gastriqueEspagne